MT-3921
Phase 2Biologic
Tanabe Pharma CorporationMT-3921 is one of 51 biologic programs targeting Spinal Cord Injury. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
190 competitors in Spinal Cord Injury
#DrugCompanyPhaseTrials
1Medrol
PfizerPhase 3
Proamatine
TakedaPhase 3
Minocin
TTriax
Phase 3
Actonel
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Cesamet
BBausch Health Americas, Inc.
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Genotropin
EMD SeronoPhase 3
Myrbetriq
AstellasPhase 2
Fampridine-SR
AAcorda Therapeutics
Phase 3
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Myelopathy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MT-3921. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company